DOCSLIB.ORG

Annual Report 2007 Summary 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2007 Summary 2 ANNUAL REPORT people passion 2007 commitment integrity excellence innovation comPanY ProFile 2 letter TO tHe SHareHolDerS 4 5 CLINICAL ProGramS 6 1. microplasmin for the treatment of “back of the eye” diseases 6 2. microplasmin for the treatment of thrombotic disease 10 3. anti-PlGF 12 4. anti-Factor viii 14 5. Staphylokinase 16 Preclinical ProGramS 18 1. anti-vPAC 18 2. PlGF 19 tHromboGenicS orGanization 20 MARY SUM Financial StatementS 29 1. General information and information concerning the responsibility for the annual brochure and for the audit of the annual accounts 36 2. Key figures 37 3. Activities of thromboGenics 38 4. Corporate Governance 43 5. Shares and shareholders 53 6. Consolidated annual accounts 55 7. Glossary 102 inveStor relationS 109 KEY FIGURES consolidated profit and loss account in €1,000 year finishing on 31 December 2007 2006 revenue 1,503 3,243 operating result (17,417) (10,426) Financial income 1,780 728 Financial expenditure (321) (426) result before taxes (15,958) (10,124) Taxes (9) (10) result for the period (15,967) (10,134) result per share (0.67) (0.57) Basic and diluted consolidated balance sheet in €1,000 year finishing on 31 December 2007 2006 Tangible fixed assets 1,057 530 Intangible assets - - Goodwill 2,586 2,586 Other current assets 8,243 2,175 Cash and cash equivalents 40,111 32,043 total assets 51,997 37,334 Total shareholders' equity 48,435 35,278 Provisions (39) 29 Debts 3,601 2,027 total liabilities and equity 51,997 37,334 Stock Price evolution € &* &!%%%!%%% shares of -%%!%%% VolumeClose &' Number +%%!%%% . )%%!%%% + '%%!%%% ( % 07 07 07 07 07 07 07 07 06 07 07 07 06 06 06 06 06 07 July July May April June March August August October October January February December December November November September September Portfolio march 2008 (for updates see www.thrombogenics.com) PRECLINICAL CLINICAL Drug candidate Indication DISCOVERY DEVELOPMENT PHASE I PHASE II PHASE III Microplasmin Vitrectomy / Vitreoretinal traction Microplasmin Diabetic retinopathy (DME) Microplasmin Stroke Staphylokinase Acute myocardial infarction Anti-factor VIII(TB-402) Deep vein thrombosis Atrial fibrillation Anti-PIGF (TB-403) Cancer Age related macular degeneration PIGF Coronary artery disease, Peripheral arterial occlusive disease Anti-VPAC Thrombocytopenia VISUAL DISORDERS CARDIOVASCULAR DISEASE CANCER ThROmbOGENics missiON “ThromboGenics develops innovative vascular biopharmaceuticals, while applying the highest scientific and ethical standards, to create sustainable value for all of its stakeholders.” 2007 REPORT ANNUAL ics GEN O mb RO h T COMPANY PROFILE diseases, visual disorders and lead to ThromboGenics generating cancer. revenues via milestone payments ThromboGenics NV (Euronext as well as royalties on commercial brussels : ThR) is a The company plans to show sales. biopharmaceutical company proof-of-concept for its products focused on the development of by taking them through to ThromboGenics was founded in therapeutics for conditions related completion of Phase ii clinical 1991 by its chairman, Professor to the vascular system. The trials. To leverage its expertise, Désiré collen, a renowned expert company has used its in-house ThromboGenics selectively forms in cardiovascular disease. The expertise and collaborations with development and marketing company currently has around 50 academic institutions to build collaborations with experienced people based at its headquarters a strong pipeline of promising partners in the pharmaceutical in Leuven, belgium, and at its ics drug candidates in cardiovascular industry. such collaborations can facilities in ireland and the U.s. OGEN mb RO h 2 T Annual Report 2007 3 ThROmbOGENics Annual Report 2007 HIGHLIGHTS January 8, 2007 April 16, 2007 November 2, 2007 ThromboGenics initiates a Phase ThromboGenics licenses to ThromboGenics announces the iib clinical trial in the U.s. with millipore its patents, data and publication of exciting data on microplasmin in vitrectomy and know-how for the manufacturing, a novel class of angiogenesis a Phase ii trial for non-surgical development and evaluation of stem inhibitors in cell. These treatment of diabetic retinopathy in cell medium technology REsGRO. experimental results demonstrate Europe. ThromboGenics will receive upfront that antibodies against PlGF can and milestone payments, and inhibit cancer tumor growth and will earn double-digit royalties on the development of metastases January 15, 2007 millipore’s sales. in preclinical models, without affecting healthy tissues. ThromboGenics and Geymonat together with other parties are May 9, 2007 awarded a 2 EUR million EU grant, November 14, 2007 of which ThromboGenics received ThromboGenics successfully EUR 776.541, for the VAsOPLUs completes a private offering, raising ThromboGenics begins preclinical development consortium, a 23.9 million euro. The funds will be development of the anti-VPAc’ research program for a new class used to further advance its clinical antibody for thrombocytopenia, a of pro-angiogenesis agents. The and preclinical programs. common and severe side-effect funded research for VAsOPLUs will of chemotherapy which increases be conducted within a consortium the risk of bleeding and severity of that will comprise ThromboGenics, September 4, 2007 hemorrhage. Geymonat (italy), Roche Diagnostics (Germany), Eurogentec (belgium) ThromboGenics announces and three expert academic groups. the successful completion of December 4, 2007 technology transfer to bharat biotech for the production of ThromboGenics presents results February 12, 2007 staphylokinase. The transfer of the vitreomacular traction paves the way for the Phase Phase i trial of Tb-402 (miVi-iiT) ThromboGenics and bioinvent iii clinical development and at the American society of Retina receive approval from the Danish commercialization of ThR-100 in specialists annual meeting. medicines Agency to initiate a emerging markets. microplasmin indicates clear Phase i clinical trial of the novel potential in “back of the eye” anticoagulant Tb-402. diseases, with treated patients September 7, 2007 achieving macular hole closure and traction release without need for March 2, 2007 ThromboGenics and bioinvent vitrectomy. announce the successful Prof. Désiré collen, chairman and completion of a Phase i trial with cEO of ThromboGenics, is awarded Tb-402 which is being developed for December 11, 2007 the 2007 harvard club of belgium the prevention of venous thrombo- Leadership Prize. embolic disorders. ThromboGenics presents results of the Phase i trial of Tb-402 at the American society of March 27, 2007 October 4, 2007 hematology annual meeting. Tb-402 development will continue GO capital, a Dutch-based asset ThromboGenics and Rhein in order to determine whether it manager, becomes a major minapharm announce a license may provide stable long-acting shareholder in ThromboGenics agreement for the production, anticoagulant action for the (approximately 5.4% of outstanding clinical development and prevention of thrombo-embolic shares). commercialization of ThR-174, disorders. the next-generation derivative of staphylokinase, in the middle East, Africa and other countries. s “We are pleased to report to you that, at the end of the first extended OLDER book year since our IPO in July 2006, ThromboGenics NV is thriving. Both our product portfolio and our finances are in good health.” h ARE sh E h LETTER TO T LETTER TO PRODuct portfolio towards the middle of 2008. for this novel approach to the - Our lead product microplasmin - Staphylokinase has a clear track treatment of cancer. is currently being evaluated in towards commercialization for - Our preclinical pipeline is Phase ii clinical trials which the treatment of heart attack progressing according to indicate that microplasmin is well in several territories of the plan, where we continue the tolerated and could provide clear developing world. development of two novel potential for treatment of “back - Our anti-Factor Viii antibody has compounds. of the eye” diseases, both as an successfully completed Phase i adjunct to surgery and as a stand- studies; interaction studies have alone treatment. been initiated to position the drug FINANCES - Additionally, microplasmin is for clinical efficacy studies in being evaluated for treatment patients with thrombotic disease. With a cash position of slightly of ischemic stroke in a Phase - Our anti-PlGF antibody is over 46 million Euro at the end ics iia study, for which we expect to undergoing initial Phase i studies. of 2007 and a burn-rate of 1.5 to complete patient recruitment We have great expectations 2.0 million Euro per month, our OGEN mb RO h 4 T Annual Report 2007 5 ThROmbOGENics Annual Report 2007 Prof. Dr. Désiré Collen Chairman of the Board of Directors present development plans can be and solidified its structure cancer) with great medical need supported for at least the next two with the recruitment of for novel treatments. This will years, even in the absence of new senior people responsible for require the continued passion corporate partnerships or licenses. intellectual property, cmc and commitment of our staff, (chemistry, manufacturing and who deserve our appreciation and controls), human resources and gratitude for helping us to achieve Organization preclinical and clinical program our mission: “to develop innovative management. vascular biopharmaceuticals, - The company moved from a while applying the highest single combined cEO/chairman to in 2008 we will assertively move scientific and
Load more

Recommended publications
  • Chemistry & Biology Interface
    270 ISSN: 2249 –4820 Chemistry & Biology Interface, 2013, 3, 4, 270-275 Chemistry & Biology Interface An official Journal of ISCB, Journal homepage; www.cbijournal.com OBITUARY Sir Robert Geoffrey Edwards (1925-2013) The World Scientific Community suffered a joined the University of Cambridge as Ford huge setback on April 10, 2013 when the Foundation Research Fellow and became a pioneer of reproductive medicine and in- Reader in Physiology in 1969. He, in vitro fertilisation (IVF) Sir Robert Geoffrey collaboration with Patrick Steptoe, a Edwards, FRS, a Nobel Prize-winning gynaecologic surgeon from Oldham General scientist died at the age of 87 after a long Hospital, developed human culture media to lung illness. allow the fertilisation and recover ovocytes from patients with tubal infertility with the Robert G. Edwards was born on 27 th help of laparoscopy, ultimately led to the September, 1925 at Batley in England. After birth of Louise Brown, the world’s first “test finishing his schooling in Manchester, he tube baby” at 11.47 PM on 25 th July, 1978. served in the British Army and then During the entire development of the completed his undergraduate studies in creation of this medical history, their biology at Bangor University. Edwards then attempts met significant hostility and moved to the University of Edinburgh and opposition, including a refusal of the studied at the Institute of Animal Genetics Medical Research Council to fund their and Embryology and earned his doctorate research and a number of lawsuits. degree in Genetics in 1955. In 1963, he 271 ISSN: 2249 –4820 Chemistry & Biology Interface, 2013, 3, 4, 270-275 In-vitro fertilisation (IVF), a process by that has revolutionized the cure of human which an egg is fertilised by sperm outside infertility, Professor Edwards was awarded the body ( in-vitro, in laboratory condition), Nobel Prize in Physiology or Medicine in has offered a new way to help infertile 2010.
    [Show full text]
  • Fondation Francqui-Stichting Fondation D’Utilité Publique - Stichting Van Openbaar Nut
    Fondation Francqui-Stichting Fondation d’Utilité Publique - Stichting van Openbaar Nut Ceremony of the Francqui Prize by Her Majesty the Queen at the "Palais des Académies" on June 9, 2015 Career - Research - Report of the Jury Stefaan Vaes Career Stefaan Vaes was born on February 29, 1976 in Herentals. He is married to Annelies Maes and the proud father of two daughters, Eline and Margot. He studied Latin-Mathematics at the Sint-Jozef high school in Herentals. Already at school, he was fascinated by mathematical problems. Laureate of the Flemish Mathematical Olympiad, he was one of the six Belgian team members at the 1994 International Mathematical Olympiad in Hong Kong. Motivated by inspiring high school teachers, he started his mathematics studies at KU Leuven, where he obtained his degree in 1998. The same year, he started a PhD in mathematics with a PhD fellowship of the Fund for Scientific Research (FWO) and with Alfons Van Daele as his advisor. During his PhD research, he collaborated intensively with Johan Kustermans and they developed the theory of locally compact quantum groups. That was also the title of the PhD thesis that Stefaan Vaes defended in 2001 at KU Leuven and that was rewarded with the Robert Stock Prize of the Academische Stichting Leuven. The FWO offered him the opportunity to spend the final year of his PhD fellowship in Paris, in one of the world’s main research centers in functional analysis. Stefaan Vaes started to work in the operator algebra research group lead by Georges Skandalis. The vast dynamism of this group and the enormous offer of seminars and courses by mathematicians from all over the world marked a turning point in his career.
    [Show full text]
  • FRANCQUI-COLLEN-PRIJS 2020 Persmap
    Fondation F R A N C Q U I Stichting Fondation d’Utilité Publique Stichting van Openbaar Nut www.francquifoundation.be FRANCQUI-COLLEN-PRIJS 2020 Persmap Voor meer informatie: Annelies Baeten [email protected] 0494/64.76.23 Inhoud Het curriculum van de laureaten............................................................................................................. 3 Cédric Blanpain .................................................................................................................................... 3 Bart Loeys ............................................................................................................................................ 4 De Francqui-Stichting en de Francqui-Prijs ............................................................................................. 5 Het ontstaan van de Francqui-Stichting .............................................................................................. 5 De Francqui-Prijs ................................................................................................................................. 5 Francqui-Prijs 2020: de leden van de jury ............................................................................................... 6 Francqui-Prijs: de laureaten van de voorbije 10 jaar .............................................................................. 8 Het curriculum van de laureaten Cédric Blanpain Cédric Blanpain werd op 6 september 1970 geboren in Ukkel. Voor zijn secundair onderwijs trok hij naar het Collège Saint-Hubert in Watermaal-Bosvoorde.
    [Show full text]
  • Les Colloques Internationaux
    Fondation Francqui-Stichting Fondation d’Utilité Publique - Stichting van Openbaar Nut Ceremony of the Francqui Prize at the Fondation Universitaire on July 15, 1960 Curriculum Vitae - Report of the Jury Christian de Duve Curriculum Vitae Born at Thames-Ditton (G.-B.), on October 2, 1917 University diplomas : Doctor of medicine, Katholieke Universiteit Leuven, 1941 Graduate of higher education, Katholieke Universiteit Leuven, 1945 Licentiate in chemical sciences, Katholieke Universiteit Leuven, 1946 Functions : Full Professor at the faculty of medecine of the Katholieke Universiteit Leuven : physiological chemistry, biochemistry and cellular biochemistry Professor at the Rockefeller University, New York: biochemical cytology Curriculum vitae : Assistant at the Katholieke Universiteit Leuven, 1941-1944 Candidate of the "Nationaal Fonds voor Wetenschappelijk Onderzoek", 1944- 1946 Grant holder of the Foundation “Stiftelsen Therese och Johan Andersons minne”, Stockholm, 1946-1947 Research Fellow of the Rockefeller Foundation, 1947-1948 Part-time lecturer at the Katholieke Universiteit Leuven, 1947-1951 Member of the sections “Natural science”, “Natural science and biological Sciences” and “chemical Sciences” of Jurys of the Prize Louis Empain, 1949,1953 and 1955; Chairamn of the section “Natural science”, 1960-1966 Full Professor, 1951 Member of the Board of the Foundation “De Belgische Jeugd in het Buitenland, 1955-1961 Member of the scientific committee of the "Fonds voor Wetenschappelijk Geneeskundige Onderzoek, 1957-1962. Member of the
    [Show full text]
  • Annual Report 2014-2015
    ANNUAL REPORT 2014-2015 RESEARCH AND ECONOMETRICS CENTER FOR OPERATIONS CONTENTS 05 PRESENTATION 09 RESEARCH ACHIEVEMENTS AND RECOGNITION 23 TRAINING 47 SCIENTIFIC EXCHANGES AND COLLABORATIONS 69 PEOPLE 83 SUPPORT 95 STATISTICS 1 PRESENTATION > PREAMBLE > RESEARCH DIRECTIONS > RESEARCH ACHIEVEMENTS AND RECOGNITION > TRAINING > SCIENTIFIC EXCHANGES AND COLLABORATIONS > PEOPLE > SUPPORT ) CORE Annual Report 2014-2015 PRESENTATION PREAMBLE Founded in 1966, the Center for Operations Research and Econometrics (CORE) is an interdisciplinary research center of the Université catholique de Louvain. In 2010, CORE became one of the poles of IMMAQ, a research institute associating researchers from three different research entities: CORE, IRES (Institut de Recherches Economiques et Sociales) and ISBA (Institute of Statistics, Biostatistics and Actuarial Sciences). CORE follows three objectives. The first objective is the development of scientificresearch in the fields of economics, econometrics, operations research and quantitative and economic geography. The second objective is the training of young researchers at the doctoral and postdoctoral stages of their career. The third objective is the promotion of local and international scientific exchanges and collaborations. This report gives an overview of the activities developed in the period from Summer 2014 to Summer 2015 to meet these objectives. A more dynamic follow-up of the current activities can be found in the CORE Newsletter which is published three times a year, on the CORE website, and on social networks (Facebook, Twitter, Wikipedia). RESEARCH DIRECTIONS CORE’s activities integrate fundamental and applied research to shed analytical light on a wide range of issues arising from economic policy and the management of private and public organizations. These research activities build on a common foundation of quantitative modeling and rigorous mathematical reasoning, encompassing many different fields of human activity.
    [Show full text]
  • PRIX FRANCQUI 2020 Dossier De Presse
    Fondation F R A N C Q U I Stichting Fondation d’Utilité Publique Stichting van Openbaar Nut www.francquifoundation.be PRIX FRANCQUI 2020 Dossier de presse Pour plus d’informations, contactez : Célia Roger [email protected] 0478/82.74.70 Sommaire La carrière des lauréats ........................................................................................................................... 3 Cédric Blanpain .................................................................................................................................... 3 Bart Loeys ............................................................................................................................................ 4 La Fondation Francqui et le Prix Francqui ............................................................................................... 5 Les origines de la Fondation Francqui ................................................................................................. 5 Le Prix Francqui ................................................................................................................................... 5 Prix Francqui 2020: les membres du jury ................................................................................................ 6 Prix Francqui : les lauréats des 10 dernières années .............................................................................. 8 La carrière des lauréats Cédric Blanpain Cédric Blanpain est né à Uccle le 6 septembre 1970. Il étudie au collège Saint-Hubert à Boitsfort. Cédric Blanpain commence
    [Show full text]
  • Fondation Francqui-Stichting Fondation D’Utilité Publique - Stichting Van Openbaar Nut
    Fondation Francqui-Stichting Fondation d’Utilité Publique - Stichting van Openbaar Nut Ceremony of the Francqui Prize by his Royal Majesty the King at the "Palais des Académies" on June 11, 2014 Curriculum Vitae - Work - Report of the Jury Bart Lambrecht Curriculum Vitae Bart N. Lambrecht was born on the 19th of April 1968 in Gent, Belgium. He obtained an MD degree from the University of Gent in 2003. After a first year of training in Internal Medicine, he wanted to perform more fundamental research and started a PhD project in the laboratory of Prof Romain Pauwels at Gent University. Here he became fascinated with the immunology of asthma and allergy. His PhD thesis was defended in 1999 and unraveled the role of dendritic cells (DCs) in asthma. In the meanwhile he also spent a year in the Centenary Institute of Cell Biology and Cancer Medicine in Sydney, where he studied T cell activation in the lungs, under supervision of Prof. Barbara Fazekas de St.-Groth. His PhD thesis was awarded with several prizes, including the Horlait-Dapsens Scholarship, The Boehringer-Ingelheim prize in Pulmonary Medicine, The International Schering Plough Respiratory 2000 award and the European Respiratory Society (ERS) Allergy & Clinical Immunology award. In 1998 he resumed clinical training and specialized in Pulmonary Medicine at Erasmus University in Rotterdam, The Netherlands under supervision of Prof. Henk Hoogsteden. Here, he was able to combine clinical residency and fellowship with postdoctoral work and he set up a new group studying the biology of DCs in asthma, lung cancer and lung infections, funded by the Dutch Athma Foundation and a VIDI grant of the Dutch Science Organisation (NWO).
    [Show full text]
  • Vanderhaeghen First Name: Pierre
    CURRICULUM VITAE Name: Vanderhaeghen First name: Pierre Date and place of birth: Brussels, August 30 1967 Citizenship: Belgian Languages: French, English, Dutch Professional address: Institute of Interdisciplinary Research (IRIBHM) ULB Neuroscience Institute (UNI) Université Libre de Bruxelles ULB, Campus Erasme CP 602 Bldg. C Room 6.113 808, Route de Lennik B-1070 Brussels, Belgium Pho: 32-2-555-4186 // 32-2-555-4185 Fax: 32-2-555-4655 email: [email protected] Web site: http://dev.ulb.ac.be/pvdhlab University Studies: 1992-1996, Medical school, Université Libre de Bruxelles (U.L.B., Brussels, Belgium): Ph.D. in Biomedical Sciences, May 1996: « Characterization of members of the olfactory receptor gene family that are expressed in the male germ line ». 1985-1992, Medical school, Université Libre de Bruxelles (U.L.B., Brussels, Belgium): Medical Doctor, June 1992 (Summa Cum Laude, 2nd in a class of 500). Positions: 2013-present: Director, ULB Neuroscience Institute (UNI), U.L.B. 2013-present: Full Professor, Medical school, U.L.B. 2013-2014: Visiting Professor/Investigator at the VIB Center for the Biology of Disease, K.U. Leuven. 2010-present: Deputy-Director, Institute of Interdisciplinary Research (I.R.I.B.H.M., U.L.B.). 2010-2012: Research Director at the Belgian National Fund for Scientific Research (F.N.R.S). 2006-2010: 1 Senior Group Leader (Maître de Recherches) at the Belgian National Fund for Scientific Research (F.N.R.S). 2001-2006: Group Leader (Chercheur qualifié) at the Belgian Belgian National Fund for Scientific Research (F.N.R.S) . 1999-2001: Chargé de Recherches (postdoctoral position) at the Belgian F.N.R.S.
    [Show full text]
  • Professor Michel A.J. Georges University of Liège Michel Georges
    Professor Michel A.J. Georges University of Liège Michel Georges was born in 1959 in Schoten, Belgium. He received his Doctor of Veterinary Medicine from the University of Liège in 1983, followed by a Master of Science in Molecular Biology from the Free University of Brussels in 1985. He obtained his habilitation from the University of Liège in 1991. From By studying the phenotypic characteristics of traits 1989 to 1993 Michel worked in USA, first as senior such as callipyge in sheep he and his colleagues have scientist, then director of research at Genmark Inc. and identified novel molecular mechanisms resulting from as adjunct professor in the Department of Human the perturbation of miRNA‐mediated gene regulation, Genetics in Salt Lake City, Utah. Since 1994 he has been thus acting as a pioneer in opening up the field of heading the Unit of Animal Genomics at the University epigenetics for animals. Among his present activities is of Liège. He played an instrumental role in establishing research on the processes of gene mutation and the GIGA (Interdisciplinary Cluster for Applied recombination. These processes have a direct impact on Genoproteomics) Research Institute within the phenotypes and traits such as lethality and fertility.. University of Liege. In 2006, the Unit of Animal Over the years Michel has established working Genomics became part of GIGA, and Michel Georges is relationships with the major breeding organizations in now the Research Director of GIGA. many countries, helping them to apply the results of his Michel is well known for his research in the field of discoveries on a large scale to accelerate the process of animal genetics and genomics.
    [Show full text]
  • Les Colloques Internationaux
    Fondation Francqui-Stichting Fondation d’Utilité Publique - Stichting van Openbaar Nut Ceremony of the Francqui Prize by his Royal Highness Prince Philippe at the "Palais des Académies" on June 9, 2010 Cursus - Maniquet’s works - Report of the Jury (photos of the ceremony) François Maniquet Cursus François Maniquet is a graduate in economics from the Facultés Universitaires Notre-Dame de la Paix à Namur. He completed his master thesis in 1988 under the supervision of Professor Jean-Philippe Platteau. The topic of the thesis was the theories of exploitation. Then, he spent two years at University of Peace, a not for profit organisation, founded by Dominique Pire, laureate of the Nobel Prize of Peace in 1958, active in conflict management and conflict prevention. François Maniquet is still a member of the board of directors of this organisation. Back at Facultés de Namur, he began a PhD under the supervision of Professor Louis Gevers. Since that period, François Maniquet’s main research topic has been the theory of fairness : what is a fair economy, and which institutions are most likely to lead to a fair economy. In 1992, he met Marc Fleurbaey, at that time Phd student at EHESS, Paris. As their research agendas were similar, they decided to work together. They still work together today. Their common objective is to provide definitions of a fair economy when the ethical observer considers that some inequalities are not unfair (typically, the inequalities stemming from differences in choices). After havind defended his dissertation in May 1994, François Maniquet went to the US (Duke University and University of Rochester) and to Spain (Universidad Autonoma de Barcelona) for post-doctoral stays.
    [Show full text]
  • Innovation in Healthcare
    Institute for Interdisciplinary Innovation in healthcare RESEARCH EDUCATION INNOVATION COLLABORATION ACROSS BORDERS 2 TABLE OF CONTENTS ‣ THE I3h INSTITUTE 4 • MISSION and VISION 4 • RESEARCH 4 • EDUCATION 5 • WHO WE ARE 6 • BOARD of TRUSTEES 10 • SCIENTIFIC COLLABORATORS 11 • PUBLICATIONS 12 ‣ INTERDISCIPLINARY PROGRAM in HEALTHCARE 14 INNOVATION • LECTURES 14 • WORKSHOPS 14 • CASE STUDIES 15 • FACULTY 16 ‣ WHAT'S NEXT ? 26 3 # The I3h INSTITUTE MISSION and VISION Our overarching objective is to move patient-centered healthcare forward through bridging competencies and expertise from various disciplines and fostering multi-stakeholder collaboration. As an academic institute, we aim to educate the next generation of healthcare professionals and develop new scientific knowledge on Health as a Common Good. RESEARCH Our aim is to reflect upon and develop solutions addressing the multiple challenges in the healthcare sector. We follow a system approach to mobilise collective intelligence and incentivise collaborative innovation. Key areas of interest : • Vaccine hesitancy • Patient access to healthcare innovation • Opioid crisis • Physician-industry dialogue 4 EDUCATION Benefiting from the philanthropic support of the Baillet Latour Fund, the I3h Interdisciplinary Program in Healthcare Innovation is attended by master and PhD students as well as post-doctoral researchers from several Belgian universities : In 2020, we welcome over 140 students from diverse backgrounds : • Medicine • Biomedical and Pharmaceutical sciences • Public Health • Economics and Management • Law • Bioengineering Through lectures, workshops and online learning, participants gain competencies to address scientific, business, management and social issues in the healthcare sector. 5 WHO WE ARE Michel GOLDMAN I Founder & Co-Director Michel Goldman, M.D., Ph.D., is Professor of Immunology and the Founder of the I³h Institute at the ULB.
    [Show full text]
  • And the Winner Is Philanthropic Prizes
    “And the winner is …” Capturing the promise of philanthropic prizes 2 Acknowledgements We would like to thank the many organizations and individuals who supported this research and without whom we would not have been able to undertake it. We spoke to a wide range of analysts, sponsors, administrators, and competitors in the prize sector, who are listed in full in the appendix. We thank them all for their contributions. Twelve organizations that agreed to share their experiences in more depth deserve particular recognition. These organizations arranged interviews with multiple stakeholders within their programs and often hosted members of our team on site visits. We are grateful for their time, knowledge, and insight. These people (and the organization they are currently or formerly associated with) include Robert Benedict, Charlie Brown, Sushmita Ghosh, and Karin Hilhouse (Changemakers), Evie Dennis, Jerry Dickman, Jim Hayes, Yaroslav Hetman, Bill Hybl, Peter Kramer, and Peter Maiurro (El Pomar Foundation), Dotti Irving, Jonathan Taylor, and Ion Trewin (The Man Booker Prize), Paul Gudonis, Dean Kamen, William Miller, Cecilia Neumann, Dia Stolnitz, Wendy Trommer, and Vincent Wilczynski (FIRST), Nyssim Lefford and Anil Rathi (Idea Crossing), Craig Cooney, Aubrey de Grey, Dave Gobel and Kevin Perrott (The Methuselah Foundation), Lord Cairns, Hania Farhan, Hadeel Ibrahim and Nicholas Ulanov (The Mo Ibrahim Foundation), Doug Comstock, Ken Davidian and Andrew Petro (NASA), Jim Bennett, Reed Hastings, Jon Sanders and Steve Swasey (Netflix), Charles Harper, Gary Rosen, Arthur Schwartz, and John M. Templeton, Jr. (The John Templeton Foundation), Justin Cremer, Jan Douglas, Lisa Fleming, Judith Pim, Kenneth Quinn, and Frank Swoboda (The World Food Prize Foundation), and Peter Diamandis, Bard Geesaman, Brent Kocher, Cristin Lindsay, Jaison Morgan and Tom Vander Ark (The X PRIZE Foundation).
    [Show full text]